ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Eli Lilly and Johnson & Johnson side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Eli LillyJohnson & Johnson
studies on the registry2,2623,709
open to participants now173146
phase 3 studies under way10495
reach primary completion within a year10487
programswith a study of their own in two years93+3 named only56+4 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseEli LillyJohnson & Johnson
Phase 1

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%
Phase 2

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%
Phase 3

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%
Approved, new studies

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
Johnson & Johnson25 readouts · 8 phase 3·

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Eli Lilly

New programs 8

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 27 in all. A program counts in each condition its studies name most.

ConditionEli LillyJohnson & Johnson
Carcinoma, Non-Small-Cell Lungboth · compare here

Eli Lilly in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. olomorasibphase 3
  2. Anti-PTK7/Exatecan Antibody-drug Conjugate LY4175408phase 1
  3. abemaciclibapproved, new study
  4. selpercatinibapproved, new study

Their studies: Eli Lilly’s studies of Carcinoma, Non-Small-Cell Lung in search

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

Lymphoma, Non-Hodgkinboth · compare here
Neoplasmsboth · compare here

Eli Lilly in Neoplasms: 3 programs

  1. LY4066708phase 1
  2. LY4214835phase 1
  3. LY4336619phase 1

Their studies: Eli Lilly’s studies of Neoplasms in search

Alzheimer Diseaseboth · compare here

Eli Lilly in Alzheimer Disease: 5 programs

  1. remternetugphase 3
  2. LY4405094phase 1
  3. LY3439539phase 1
  4. LY4560736phase 1
  5. donanemabapproved, new study

Their studies: Eli Lilly’s studies of Alzheimer Disease in search

Johnson & Johnson in Alzheimer Disease: 3 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. JNJ-64042056phase 2

Their studies: Johnson & Johnson’s studies of Alzheimer Disease in search

Colitis, Ulcerativeboth · compare here

Eli Lilly in Colitis, Ulcerative: 4 programs

  1. zotemtegrastphase 2
  2. LY4395089phase 2
  3. eltrekibartphase 2
  4. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Colitis, Ulcerative in search

Johnson & Johnson in Colitis, Ulcerative: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Colitis, Ulcerative in search

Crohn Diseaseboth · compare here

Eli Lilly in Crohn Disease: 4 programs

  1. zotemtegrastphase 2
  2. LY4395089phase 2
  3. clazakizumabphase 2
  4. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Crohn Disease in search

Johnson & Johnson in Crohn Disease: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Crohn Disease in search

Psoriasisboth · compare here

Eli Lilly in Psoriasis: 5 programs

  1. eltrekibartphase 2
  2. simepdekinraphase 2
  3. DC-806phase 2
  4. Tirzepatideapproved, new study
  5. mirikizumabapproved, new study

Their studies: Eli Lilly’s studies of Psoriasis in search

Johnson & Johnson in Psoriasis: 3 programs

  1. icotrokinraphase 3
  2. risankizumabphase 3
  3. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Psoriasis in search

Renal Insufficiencyboth · compare here

Eli Lilly in Renal Insufficiency: 6 programs

  1. olomorasibphase 3
  2. tersolisibphase 3
  3. lepodisiranphase 3
  4. muvalaplinphase 3
  5. pirtobrutinibapproved, new study

and 1 more — sign in to see them all

Their studies: Eli Lilly’s studies of Renal Insufficiency in search

Johnson & Johnson in Renal Insufficiency: 2 programs

  1. seltorexantphase 3
  2. olomorasibphase 2

Their studies: Johnson & Johnson’s studies of Renal Insufficiency in search

Prostatic Neoplasmsboth · compare here

Eli Lilly in Prostatic Neoplasms: 1 program

  1. abemaciclibapproved, new study

Their studies: Eli Lilly’s studies of Prostatic Neoplasms in search

Breast Neoplasmsboth · compare here

Eli Lilly in Breast Neoplasms: 4 programs

  1. Imlunestrantphase 3
  2. tersolisibphase 3
  3. GRPR-targeting Radioconjugate LY4257496phase 1
  4. abemaciclibapproved, new study

Their studies: Eli Lilly’s studies of Breast Neoplasms in search

Depressive Disorder, Majorboth · compare here

Eli Lilly in Depressive Disorder, Major: 1 program

  1. brenipatidephase 3

Their studies: Eli Lilly’s studies of Depressive Disorder, Major in search

Johnson & Johnson in Depressive Disorder, Major: 5 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. Aticaprantphase 3
  4. JNJ-89495120phase 2
  5. Esketamineapproved, new study

Their studies: Johnson & Johnson’s studies of Depressive Disorder, Major in search

Arthritis, Psoriaticboth · compare here

Eli Lilly in Arthritis, Psoriatic: 1 program

  1. clazakizumabphase 2

Their studies: Eli Lilly’s studies of Arthritis, Psoriatic in search

Johnson & Johnson in Arthritis, Psoriatic: 4 programs

  1. icotrokinraphase 3
  2. risankizumabphase 3
  3. JNJ-88545223phase 2
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Arthritis, Psoriatic in search

Arthritis, Rheumatoidboth · compare here

Eli Lilly in Arthritis, Rheumatoid: 4 programs

  1. clazakizumabphase 2
  2. sevoloprubartphase 2
  3. LY4213663phase 1
  4. baricitinibapproved, new study

Their studies: Eli Lilly’s studies of Arthritis, Rheumatoid in search

Johnson & Johnson in Arthritis, Rheumatoid: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Arthritis, Rheumatoid in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

Eli Lilly in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. pirtobrutinibapproved, new study
  2. idelalisibapproved, new study

Their studies: Eli Lilly’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Johnson & Johnson in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. fludarabinephase 2
  2. safimaltibphase 1
  3. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Alcoholismboth · compare here

Eli Lilly in Alcoholism: 3 programs

  1. brenipatidephase 3
  2. mazdutidephase 2
  3. BPL-003phase 2

Their studies: Eli Lilly’s studies of Alcoholism in search

Johnson & Johnson in Alcoholism: 1 program

  1. Aticaprantphase 3

Their studies: Johnson & Johnson’s studies of Alcoholism in search

Colorectal Neoplasmsboth · compare here

Eli Lilly in Colorectal Neoplasms: 1 program

  1. olomorasibphase 3

Their studies: Eli Lilly’s studies of Colorectal Neoplasms in search

Johnson & Johnson in Colorectal Neoplasms: 3 programs

  1. amivantamabphase 3
  2. olomorasibphase 2
  3. JNJ-89402638phase 1

Their studies: Johnson & Johnson’s studies of Colorectal Neoplasms in search

Dermatitis, Atopicboth · compare here

Eli Lilly in Dermatitis, Atopic: 2 programs

  1. baricitinibapproved, new study
  2. lebrikizumabapproved, new study

Their studies: Eli Lilly’s studies of Dermatitis, Atopic in search

Johnson & Johnson in Dermatitis, Atopic: 2 programs

  1. JNJ-95597528phase 2
  2. JNJ-95475939phase 2

Their studies: Johnson & Johnson’s studies of Dermatitis, Atopic in search

Hepatic Insufficiencyboth · compare here

Eli Lilly in Hepatic Insufficiency: 3 programs

  1. eloralintidephase 3
  2. Imlunestrantphase 3
  3. olomorasibphase 3

Their studies: Eli Lilly’s studies of Hepatic Insufficiency in search

Johnson & Johnson in Hepatic Insufficiency: 1 program

  1. olomorasibphase 2

Their studies: Johnson & Johnson’s studies of Hepatic Insufficiency in search

Arthritis, Juvenileboth · compare here

Eli Lilly in Arthritis, Juvenile: 1 program

  1. baricitinibapproved, new study

Their studies: Eli Lilly’s studies of Arthritis, Juvenile in search

Johnson & Johnson in Arthritis, Juvenile: 2 programs

  1. risankizumabphase 3
  2. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Arthritis, Juvenile in search

Asthmaboth · compare here

Eli Lilly in Asthma: 2 programs

  1. brenipatidephase 3
  2. lebrikizumabapproved, new study

Their studies: Eli Lilly’s studies of Asthma in search

Johnson & Johnson in Asthma: 1 program

  1. JNJ-95597528phase 2

Their studies: Johnson & Johnson’s studies of Asthma in search

Lupus Erythematosus, Systemicboth · compare here

Eli Lilly in Lupus Erythematosus, Systemic: 2 programs

  1. LY4298445phase 1
  2. baricitinibapproved, new study

Their studies: Eli Lilly’s studies of Lupus Erythematosus, Systemic in search

Johnson & Johnson in Lupus Erythematosus, Systemic: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Lupus Erythematosus, Systemic in search

Depressive Disorder, Treatment-Resistantboth · compare here

Eli Lilly in Depressive Disorder, Treatment-Resistant: 1 program

  1. BPL-003phase 2

Their studies: Eli Lilly’s studies of Depressive Disorder, Treatment-Resistant in search

Johnson & Johnson in Depressive Disorder, Treatment-Resistant: 1 program

  1. Esketamineapproved, new study

Their studies: Johnson & Johnson’s studies of Depressive Disorder, Treatment-Resistant in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Eli Lilly in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. idelalisibapproved, new study

Their studies: Eli Lilly’s studies of Lymphoma, Large B-Cell, Diffuse in search

Johnson & Johnson in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Lymphoma, Large B-Cell, Diffuse in search

Lymphoma, Mantle-Cellboth · compare here

Eli Lilly in Lymphoma, Mantle-Cell: 1 program

  1. pirtobrutinibapproved, new study

Their studies: Eli Lilly’s studies of Lymphoma, Mantle-Cell in search

Johnson & Johnson in Lymphoma, Mantle-Cell: 1 program

  1. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Lymphoma, Mantle-Cell in search

Osteoarthritis, Kneeboth · compare here

Eli Lilly in Osteoarthritis, Knee: 1 program

  1. LY4065967phase 2

Their studies: Eli Lilly’s studies of Osteoarthritis, Knee in search

Johnson & Johnson in Osteoarthritis, Knee: 1 program

  1. lazertinibphase 3

Their studies: Johnson & Johnson’s studies of Osteoarthritis, Knee in search

Primary Myelofibrosisboth · compare here

Eli Lilly in Primary Myelofibrosis: 1 program

  1. idelalisibapproved, new study

Their studies: Eli Lilly’s studies of Primary Myelofibrosis in search

Johnson & Johnson in Primary Myelofibrosis: 1 program

  1. bleximenibphase 3

Their studies: Johnson & Johnson’s studies of Primary Myelofibrosis in search

Sleep Apnea, Obstructiveboth · compare here

Eli Lilly in Sleep Apnea, Obstructive: 1 program

  1. eloralintidephase 3

Their studies: Eli Lilly’s studies of Sleep Apnea, Obstructive in search

Johnson & Johnson in Sleep Apnea, Obstructive: 1 program

  1. seltorexantphase 3

Their studies: Johnson & Johnson’s studies of Sleep Apnea, Obstructive in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Eli Lilly 50 of 93 · Johnson & Johnson 33 of 56 programs (40 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3, Johnson & Johnson: 4).